SECsense Logo

Ascendis Pharma A/S February 2025 Form 6-K: Financial Results & SEC Compliance

$ASND
Form 6-K
Filed on: 2025-02-12
Source
Ascendis Pharma A/S February 2025 Form 6-K: Financial Results & SEC Compliance

Here are the key insights extracted from the provided section of the financial report:

  1. Form Type: This document is a Form 6-K, which is typically used by foreign companies to report significant events to the SEC.
  2. Company Information:
  • Name: Ascendis Pharma A/S
  • Principal Executive Office Address: Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
  • Commission File Number: 001-36815.
  1. Reporting Period: The financial report pertains to the month of February 2025, and it includes the financial results for the year ended December 31, 2024.
  2. Exhibit: The report includes Exhibit 99.1, which is a press release dated February 12, 2025, announcing the company's financial results.
  3. Signature and Authority: The report is signed by Michael Wolff Jensen, who is the Executive Vice President and Chief Legal Officer of Ascendis Pharma A/S. The date of the signature is February 12, 2025.
  4. Regulatory Compliance: The document indicates compliance with the Securities Exchange Act of 1934, as amended.
  5. Checkmarks for Reporting: There are indications for whether the registrant files annual reports under Form 20-F or Form 40-F, but the specific responses are not included in the text provided.

Overall, this section serves as a formal notification of financial results and compliance with SEC regulations by Ascendis Pharma A/S, providing essential details about the company, the report, and the signatory.